Abchir, Oussama Khedraoui, Meriem Nour, Hassan Yamari, Imane Errougui, Abdelkbir Samadi, Abdelouahid Chtita, Samir
Published in
Pharmaceuticals (Basel, Switzerland)
In response to the increasing prevalence of diabetes mellitus and the limitations associated with the current treatments, there is a growing need to develop novel medications for this disease. This study is focused on creating new compounds that exhibit a strong inhibition of alpha-glucosidase, which is a pivotal enzyme in diabetes control. A set o...
Mascarenhas-Melo, Filipa Diaz, Mariana Gonçalves, Maria Beatriz S Vieira, Pedro Bell, Victoria Viana, Sofia Nunes, Sara Paiva-Santos, Ana Cláudia Veiga, Francisco
Published in
Pharmaceuticals (Basel, Switzerland)
Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars. These products boast comparable levels of safety, quality, and effectiveness to their precursor reference products. Biosimilars, al...
Alaa Eldeen, Muhammad Mamdouh, Farag Abdulsahib, Waleed K Eid, Refaat A Alhanshani, Ahmad A Shati, Ayed A Alqahtani, Youssef A Alshehri, Mohammed A Samir A Zaki, Mohamed Soltan, Mohamed A
...
Published in
Pharmaceuticals (Basel, Switzerland)
Replication Factor C Subunit 4 (RFC4), an oncogene implicated in many human cancers, has yet to be extensively studied in many cancer types to determine its expression patterns and tumor tissue function. Various bioinformatics tools were used to analyze RFC4 as a potential oncogene and therapeutic target across many cancers. We first examined RFC4 ...
Mujammami, Muhammad Aleidi, Shereen M Buzatto, Adriana Zardini Alshahrani, Awad AlMalki, Reem H Benabdelkamel, Hicham Al Dubayee, Mohammed Li, Liang Aljada, Ahmad Abdel Rahman, Anas M
...
Published in
Pharmaceuticals (Basel, Switzerland)
Metformin is the first-line oral medication for treating type 2 diabetes mellitus (T2DM). In the current study, an untargeted lipidomic analytical approach was used to investigate the alterations in the serum lipidome of a cohort of 89 participants, including healthy lean controls and obese diabetic patients, and to examine the alterations associat...
Zhang, Yun Weh, Katherine M Tripp, Bridget A Clarke, Jennifer L Howard, Connor L Sunilkumar, Shruthi Howell, Amy B Kresty, Laura A
Published in
Pharmaceuticals (Basel, Switzerland)
We recently reported that cranberry proanthocyanidins (C-PACs) inhibit esophageal adenocarcinoma (EAC) by 83% through reversing reflux-induced bacterial, inflammatory and immune-implicated proteins and genes as well as reducing esophageal bile acids, which drive EAC progression. This study investigated whether C-PACs' mitigation of bile reflux-indu...
Morè, Sonia Corvatta, Laura Manieri, Valentina Maria Morsia, Erika Poloni, Antonella Offidani, Massimo
Published in
Pharmaceuticals (Basel, Switzerland)
In multiple myeloma impressive outcomes have improved with the introduction of new therapeutic approaches, mainly those including naked monoclonal antibodies such as daratumumab and isatuximab. However, moving to earlier lines of therapy with effective anti-myeloma drugs led to an increase in the number of patients who developed multi-refractorines...
Paskas, Svetlana Stockmann, Philipp Mijatović, Sanja Kuhnert, Lydia Honscha, Walther Hey-Hawkins, Evamarie Maksimović-Ivanić, Danijela
Published in
Pharmaceuticals (Basel, Switzerland)
The ABCG2 transporter protein, as part of several known mechanisms involved in multidrug resistance, has the ability to transport a broad spectrum of substrates out of the cell and is, therefore, considered as a potential target to improve cancer therapies or as an approach to combat drug resistance in cancer. We have previously reported carborane-...
Latifi-Navid, Hamid Barzegar Behrooz, Amir Jamehdor, Saleh Davari, Maliheh Latifinavid, Masoud Zolfaghari, Narges Piroozmand, Somayeh Taghizadeh, Sepideh Bourbour, Mahsa Shemshaki, Golnaz
...
Published in
Pharmaceuticals (Basel, Switzerland)
Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible visual impairment in the elderly. The current management of nAMD is limited and involves regular intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF). However, the effectiveness of these treatments is limited by overlapping and compe...
Eriksson, Olof Velikyan, Irina
Published in
Pharmaceuticals (Basel, Switzerland)
Fibrosis accompanies various pathologies, and there is thus an unmet medical need for non-invasive, sensitive, and quantitative methods for the assessment of fibrotic processes. Currently, needle biopsy with subsequent histological analysis is routinely used for the diagnosis along with morphological imaging techniques, such as computed tomography ...
Vassallo, Valentina Di Meo, Celeste Toro, Giuseppe Alfano, Alberto Iolascon, Giovanni Schiraldi, Chiara
Published in
Pharmaceuticals (Basel, Switzerland)
Currently, chondroitin sulfate (CS) and hyaluronic acid (HA) pharma-grade forms are used for osteoarthritis (OA) management, CS as an oral formulations component, and HA as intra-articular injective medical devices. Recently, unsulfated chondroitin, obtained through biofermentative (BC) manufacturing, has been proposed for thermally stabilized inje...